Clinical trials: Proteinuria, open to volunteers
Albuminuria, Type 2 Diabetes Mellitus (T2DM)
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in…
- Conditions
- Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases
- Trial name
- NCT07667517
- Testing
- Finerenone (BAY 94-8862)
- Where
- 13 sites in China
- Volunteers
- 148 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Diabetic Kidney Disease
Oxygen Therapy in Diabetic Kidney Disease
Diabetic kidney disease (DKD) is the most significant cause of end-stage kidney disease (ESKD). Albuminuria, evolving from microalbuminuria to nephrotic-range proteinuria, is a clinical hallmark of diabetic nephropathy (DN).
- Trial name
- NCT06959485
- Testing
- Oxygen Therapy
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
IgA Nephropathy (IgAN)
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of…
- Trial name
- LUMINA IgAN (NCT07850752)
- Testing
- zigakibart, atrasentan
- Volunteers
- 340 people
- Sponsor
- Novartis Pharmaceuticals
Albuminuria
Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes
Kidney disease is a common problem among people with type 1 diabetes and can lead to disability, dialysis, and early death. Inflammation plays a key role in the development of kidney disease in type 1 diabetes and targeting…
- Trial name
- NCT05498116
- Testing
- Montelukast
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Pre-Eclampsia, Intrauterine Growth Restriction
PEPPI Study: Identification of Women at Risk for Placental Dysfunction
The main purpose of this study is to evaluate Fetal Medicine Foundation's pre-eclampsia risk calculator using maternal characteristics, first trimester serum placental growth factor (PlGF) and mean arterial pressure (MAP) in a…
- Conditions
- Pre-Eclampsia, Intrauterine Growth Restriction, Polycystic Ovary Syndrome, Iron-deficiency
- Trial name
- NCT06115122
- Testing
- Pre-eclampsia screening program
- Where
- Finland
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Oulu University Hospital
Nephritis
Characterization of Renal Microvascular Alterations in Patients With Active Urinary Sediment and/or Proteinuria Using Ultrasound Localization Microscopy
The goal of this study is the non-invasive visualization and quantification of renal microvascular dynamics in adult kidneys with proteinuria and/or active sediment.
- Trial name
- VARIOUS (NCT07469059)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Kidney Transplant; Complications
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs).
- Trial name
- NCT06059664
- Testing
- Finerenone Oral Tablet
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Diabetic Kidney Disease
Efficacy and Safety of LC-Z300-01 on Proteinuria in Diabetic Patients
The purpose of this RCT is to investigate the efficacy and safety of Sugar cane polysaccharide LC-Z300-01 on proteinuria in participants with diabetic kidney disease (DKD).
- Trial name
- NCT06686758
- Testing
- Sugar cane polysaccharide, Control
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Changzheng Hospital
IgA Nephropathy
Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy
This study is testing whether a medicine called mycophenolate mofetil (MMF) works better than the usual treatment for people whose kidney disease, called IgA nephropathy, has not improved with standard care.
- Trial name
- NCT07785128
- Testing
- Mycophenolate Mofetil (MMF), Prednisolon
- Where
- 3 sites in Bangladesh
- Volunteers
- 104 people
- Sponsor
- Shaheed Suhrawardy Medical College and Hospital
Nephrotic Syndrome
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome.
- Trial name
- SGLT2-NS (NCT07214818)
- Testing
- Dapagliflozin, Empagliflozin, Standard Therapy
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Mansoura University
Focal Segmental Glomerulosclerosis
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07268638
- Testing
- Praliciguat (Part A), Praliciguat (Part B)
- Where
- 30 sites in United States
- Volunteers
- 60 people
- Sponsor
- Akebia Therapeutics
Type 2 DM, Type 2 DM /Diabetic Nephropathy
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
Title: Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes.
- Conditions
- Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria
- Trial name
- SIGNAL (NCT06954090)
- Testing
- Semaglutide, 1.34 mg/mL, Finerenone Oral Tablet, Dapagliflozin (DAPA)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Steno Diabetes Center Copenhagen
Chronic Kidney Disease, Type 2 Diabetes
RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes…
- Trial name
- NCT07605390
- Testing
- Epic-Based Clinician Notification, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Baylor Research Institute
IC-MPGN
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative…
- Trial name
- APPARENT (NCT05755386)
- Testing
- iptacopan
- Where
- 131 sites in United States, Argentina and 21 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
C3 Glomerulopathy, Complement-mediated Kidney Disease
CHART-C3G/CLNP023B12011
This is a non-interventional chart abstraction cohort study with longitudinal follow up. Patients with C3G treated with iptacopan will be enrolled and characterized (i.e., systematically describe and summarize) regarding their…
- Conditions
- C3 Glomerulopathy, Complement-mediated Kidney Disease, Proteinuria
- Trial name
- NCT07331259
- Testing
- Iptacopan
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Immunoglobulin A Nephropathy (IgAN)
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN.
- Trial name
- Verdant (NCT07773727)
- Testing
- ARGX-121
- Where
- 11 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- argenx
IgA Nephropathy (IgAN)
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN).
- Trial name
- NCT07902817
- Testing
- JADE101
- Where
- 4 sites in United States
- Volunteers
- 480 people
- Sponsor
- Jade Biosciences, Inc.
Henoch Schönlein Purpura Nephritis
Finerenone Therapy for Pediatric HSPN With Mild Proteinuria
Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease.
- Trial name
- FICHSPN (NCT07315191)
- Testing
- ACEI / ARB+finerenone, ACEI/ARB
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Capital Institute of Pediatrics, China
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA.
- Trial name
- EMPA-CKD (NCT07175051)
- Testing
- Empagliflozin (oral)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago